Hypertension (HTN) accounts for 6% of death worldwide. The prevalence of HTN varies being lowest in rural India (3.4% in men and 6.8% in women), and highest in Poland (68.9% in men and 72.5% in women).
1
HTN is a risk factor for cardiovascular diseases including stroke and myocardial infarction.
There are two types of HTN. Primary or essential which accounts for 90 to 95% and its etiology is not known. Secondary HTN which accounts for 5 to 10% and its etiology is known.
Advanced glycation end products (AGEs) and its cellular receptor (RAGE) may play a role in the pathophysiology of HTN. Interaction of AGEs with RAGE increases the expression and release of inflammatory cytokines, generation of reactive oxygen species (ROS), and activates nuclear factor kappa-B (NF-κB).
2-4 These agents might affect the structures of arterial wall and/or produce contraction of the arterial wall. Various measures are available for the prevention and treatment of HTN. 5 However, very little attention has been given to the role of AGEs and its receptors in initiation and maintenance of arterial stiffness and HTN.
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Abstract
There is a close relationship between arterial stiffness and blood pressure. The studies suggest that the advanced glycation end products (AGEs) and its cell receptor (RAGE) are involved in the arterial stiffness in two ways: changes in arterial structure and vascular function. Plasma levels of AGEs and expression of RAGE are elevated, while the levels of soluble RAGE (sRAGE) and endogenous secretory RAGE (esRAGE) are lowered in patients with hypertension (HTN). There is a positive correlation between plasma levels of AGEs and arterial stiffness, and an inverse association between arterial stiffness/HTN, and serum levels of sRAGE and esRAGE. Various measures can reduce the levels of AGEs and expression of RAGE, and elevate sRAGE. Arterial stiffness and blood pressure could be reduced by lowering the serum levels of AGEs, and increasing the levels of sRAGE. Levels of AGEs can be lowered by reducing the consumption of AGE-rich diet, short duration of cooking in moist heat at low temperature, and cessation of cigarette smoking. Drugs such as aminoguanidine, vitamins, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II receptor blockers, statins, and metformin inhibit AGE formation. Alagebrium, an AGE breakers reduces levels of AGEs. Clinical trials with some drugs tend to reduce stiffness. Systemic administration of sRAGE has beneficial effect in animal studies. In conclusion, AGE-RAGE axis is involved in arterial stiffness and HTN. The studies suggest that inhibition of AGEs formation, reduction of AGE consumption, blockade of AGE-RAGE interaction, suppression of RAGE expression, and exogenous administration of sRAGE may be novel therapeutic strategies for treatment of arterial stiffness and HTN.
This review focuses on the mechanism of HTN especially systolic HTN, AGEs and RAGE axis, mechanism of AGE-RAGE axis in the development of HTN and arterial stiffness, effects of AGE and soluble receptors for AGE (sRAGE) on the elasticity of blood vessels, and measures to lower levels of AGEs and elevate the levels of sRAGE in blood in the management of arterial stiffness and HTN.
Hypertension
In each cardiac cycle, the highest pressure is called systolic and the lowest pressure is called diastolic pressure. Systolic pressure is determined by stroke volume, peak systolic rate of cardiac ejection, and arterial compliance. The factors that determine the diastolic pressure include total peripheral vascular resistance, heart rate, systolic pressure, and arterial elastic recoil. Pulse pressure (PP) is the difference between systolic and diastolic pressures and is approximately half of the diastolic pressure.
6 PP depends on cardiac output, com- 
Mechanism of Vascular Stiffness
Arterial stiffness depends on structural and functional components of artery. The arterial wall is composed of intima, 
AGE-RAGE Axis
AGEs are heterogenous group of irreversible adducts formed by the nonenzymatic glycation and glycoxidation of proteins, nucleic acid, and lipids with reducing sugars.
20,21
There are three receptors for AGEs: full length RAGE, Ntruncated RAGE, and C-terminal RAGE which has two isoforms, cleaved RAGE (cRAGE) and endogenous secretory RAGE (esRAGE 
30,31

Mechanism of AGE-Induced Hypertension
AGEs can induce HTN in two ways: alteration in arterial compliance/stiffness and interaction of AGEs with RAGE on cell surface resulting in changes in cell function.
Alteration in Arterial Stiffness
Causes of increased stiffness are fragmentation of elastin, increased amount of collagen, glycation of elastin, collagen, and cross-linking of collagen with AGEs. Arterial stiffness is composed of two components: structural and dynamic. Structural component comprises extracellular matrix (elastin and collagen). The dynamic component is the tone in the arterial smooth muscle which is dependent on endothelial cell function. Endothelium releases vasoactive substances such as NO and endothelin-1. AGEs are formed in the proteins of extracellular matrix. Accumulation of AGEs on protein of extracellular matrix leads to the formation of cross-links, which trap other local macromolecules. 32 The properties of collagen are altered through AGE-RAGE intermolecular covalent bond or cross-linking.
33
Cross-linking of AGE on collagen and elastin increases the extracellular matrix area which increases the stiffness of the artery. 34 Glycation increases the synthesis of collagen.
35
Cross-linking make the collagen insoluble to hydrolytic enzymes. 36 AGE-linked collagen is less susceptible to hydrolytic turn over and is stiffer. There is a cross-linking of AGE with elastin which reduces the elasticity of the arterial wall. Crosslinking increases the amount of collagen and decreases the amount of elastin in the arterial wall.
Other mechanisms such as reduced NO and increased endothelin-1, neuroendocrine signaling, and impaired glucose tolerance besides structural changes in the artery (collagen and elastin fibers) may be involved in the arterial stiffness by AGEs.
AGEs reduce the bioavailability and activity of NO through various mechanisms. Matrix-bound AGEs inhibit antiproliferative activity of NO, 37 reduce the half-life of NO synthase (eNOS), 38 impair NO production, 39 quench and inactivate NO, 40 reduce production of prostacyclin, 41 and increase the expression of endothelin-1. 42 Impaired glucose tolerance enhances nonenzymatic glycation of proteins with covalent cross-linking of collagen and alters the mechanical properties of interstitial tissue of arterial walls.
10
Neuroendocrine signaling can also affect the arterial stiffness. Angiotensin-II increases the formation of AGE and vice versa.
43 Increased levels of angiotensin can then increase the arterial stiffness through AGE or through release of oxygen radicals by interaction of AGE with RAGE. Angiotensin can increase oxygen radicals through various ways. 18 ROS degrades the elastin molecules in vitro. 44 ROS can modify newly synthesized tropoelastin and impair the assembly of tropoelastin into elastin fibers.
45
AGEs may contribute to endothelial dysfunction and vascular stiffness.
Interaction of AGEs with RAGE Resulting in Changes in Vascular Functions
As mentioned earlier, interaction of AGE with RAGE increases the production of ROS, such as superoxide anion (O 2 À ), hydrogen peroxide (H 2 O 2 ) and hydroxyl radicals (•OH). Superoxide anions produces contraction of the isolated rabbit aorta that is endothelium dependent and is partially mediated by an arachidonic acid metabolism. 46 H 2 O 2 in lower concentration produces contraction, while in higher concentration, it produces transient relaxation followed by contraction of isolated rabbit aorta. 47 In vivo, in canine model, ROS generated by polymorphonuclear leukocytes and administration of oxygen radical increase total peripheral vascular resistance. 48, 49 These data suggest that AGEs, through production of ROS, may induce HTN irrespective of arterial stiffness. reported that for every 2 mm Hg increase in systolic pressure increases the risk of stroke by 7% and fatal ischemic heart disease events by 5%.
Levels of AGEs, sRAGE, and esRAGE in Arterial Stiffness/Hypertension
Since AGEs have been reported to increase the stiffness of arterial wall and systolic blood pressure, and since the ROS produced by interaction of AGEs with RAGE produces vascular contraction, one would expect increases in the serum levels of AGEs, and decreases in the levels of sRAGE and esRAGE.
Serum Levels of AGEs and Arterial Stiffness/ Hypertension
Plasma levels of methylglyoxal (MG), a source of AGE, were elevated in spontaneously hypertensive rats (SHR) in comparison to normotensive Wistar-Kyoto rats. 52 The increases in MG were positively correlated with the age of the SHR.
McNulty et al 53 have reported that the plasma levels of AGEs were significantly higher in untreated hypertensive patients than in normotensive subjects (7.84 AE 0.94 vs. 2.97 AE 0.94 µg/mL).
Serum Levels of sRAGE and Arterial Stiffness/ Hypertension
Liu et al 50 measured the serum levels of sRAGE in 209 patients with essential HTN and showed that these patients had lower serum levels of sRAGE those with LVH than without LVH. Serum sRAGE levels were measured in 1,077 subjects from general population by Mayer et al.
54
They showed that the levels of sRAGE were lower in nondiabetic hypertensive patients. Heidland et al 55 have
reported that plasma levels of sRAGE are lower in patients with essential HTN. Geroldi et al, 56 on the contrary, in a cross-sectional case-control study with never treated patients of essential HTN and normotensive, showed a weak association between sRAGE and systolic blood pressure. The association between sRAGE and PP, however, was very strong. The data on the whole suggest that serum sRAGE levels are low in patients with HTN /arterial stiffness. showed a weak association between serum levels of esRAGE and IMT. Choi et al 74 showed a negative correlation between serum levels of esRAGE and systolic and diastolic blood pressure in diabetic patients treated with diet alone and metformin or sulfonylurea. esRAGE did not show any correlation with ankle-brachial PWV. It has also been reported that esRAGE was inversely related to IMT. 75 It has been shown that the serum levels of esRAGE are inversely associated with the blood pressure, especially systolic in male nondiabetic patients with obstructive sleep apnea. These data suggest that, in general, low levels of esRAGE are associated with arterial stiffness and HTN.
Therapeutic Interventions for Arterial Stiffness/Hypertension
HTN and arterial stiffness interact with each other in a bidirectional manner. 76, 77 Arterial stiffness and HTN are closely associated with age. 8 Considering the above concept, reduction in the levels of AGEs, suppression of expression of RAGE, and elevation of the levels of sRAGE and esRAGE would decrease the arterial stiffness and blood pressure. Since the interaction of AGEs with RAGE increases the formation of ROS which constricts the blood vessels, the lowering of the levels of AGEs and increasing the levels of sRAGE or esRAGE would reduce the blood pressure. The following measures should be taken to reduce the levels of AGEs, suppress the expression of RAGE, and increase the levels of sRAGE and esRAGE.
Reduction in consumption of AGEs (a) Reduction in consumption of AGE-rich diet
The consumption of glucose should be reduced because glucose is involved in the formation of AGEs. 20 Consumption of some foods such as red meat, cheese, cream, butter, animal fat, and sweetened fatty cookies which are high in AGEs should be reduced. 78 It has been reported that diets such as butter, cream, cheese, margarine, and mayonnaise have highest amount of AGEs than oil and nuts. 79 Uribarri et al 79 also
reported that among the meat group, beef has the highest amount of AGEs, followed by poultry, pork, fish, and eggs. The lowest amounts of AGEs are present in grains, legumes, breads, vegetables, fruits, and milk. Fat-free milk has lower AGEs than the whole milk.
(b) Cooking
Uriharri et al 79 reported that cooking at high temperature in dry heat increases the formation of AGEs. Frying, boiling, grilling, and roasting produce more AGEs than poaching, stewing, steaming, and boiling. Uribarri et al 79 also showed that short duration cooking in moist heat at low temperature reduces the formation of AGEs. Only 10% of the diet-derived AGEs are absorbed from gastrointestinal tract and a significant amount remains in the body for 3 days after ingestion.
80 Short-term restriction of consumption of AGEs in diet in healthy or diabetic individuals significantly decreased the serum levels of AGEs. 81 Diet low in AGEs given for 2 months to mice reduced the serum levels of AGEs.
82
(c) Cessation of cigarette smoking is beneficial because cigarette smoking increases the levels of AGEs. 
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shown to prevent diabetic vascular complications in animal model of diabetes. 86 It reduces AGE hemoglobin independent of reduction of HbA 1C in clinical trial. 87 In a placebo controlled clinical trial, aminoguanidine reduced glomerular filtration rate and urinary proteinuria, and prevented deterioration of retinopathy.
88
Further clinical trials of aminoguanidine were terminated due to concerns over long-term toxicity such as patients developing myeloperoxidase and antineutrophil antibodies and glomerulonephritis.
89
(i 
118
Curcumin downregulates the expression of RAGE in cultured hepatic cells. 119 Calcium channel blocker, nifedipine suppresses the expression of RAGE in the endothelial cells exposed to AGEs.
120
Elevation of the Levels of sRAGE and esRAGE
Statins
Treatment with pitavastatin and pravastatin increased the serum levels of sRAGE in humans. 101 Atorvastatin, fluvastatin, and lovastatin increase the serum levels of sRAGE in isolated cell lines. 121 Atorvastatin increases the levels of sRAGE and esRAGE in vitro.
121,122
ACE Inhibitors
Ramiprilat increased the expression of sRAGE in the aorta of streptozotocin-induced diabetic rats. 123 Forbes et al 123 also
reported that ramipril significantly increased the serum, a level of sRAGE in diabetic rats. Perindopril elevated the levels of serum sRAGE in patients with type 1 diabetes.
123
Angiotensin II Receptor Blocker
Telmisartan reduces the serum levels of sRAGE by decreasing its secretion.
116
Antidiabetic Drug
Tan et al 124 reported an increase in the serum levels of sRAGE and esRAGE with rosiglitazone in patients with type 2 diabetes.
Systemic Administration of Recombinant sRAGE
The studies indicate that the elevated levels of serum sRAGE are associated with an improvement in arterial stiffness and isolated systemic HTN. 
128
These observations suggest the possibility of exogenous administration of recombinant sRAGE is to raise the serum levels of sRAGE and reduce the arterial stiffness and high blood pressure especially old age isolated systemic HTN. However, till now, no data are available on the exogenous administration of recombinant sRAGE in patients with arterial stiffness and HTN.
Effects of Therapeutic Interventions on Arterial Stiffness/Hypertension
Statins, which reduces the levels of AGEs and raises the levels of sRAGE, also reduces the arterial stiffness. Atorvastatin (10 mg/daily) produced improvement in arterial stiffness in hypertensive and hypercholesteremic subject.
129 Atorvastatin improved the arterial stiffness in patients with ischemic heart disease. 130 Fluvastatin had variable effects on arterial stiffness. Rizos et al 131 reviewed nine control randomized trials with fluvastatin on arterial stiffness. Fluvastatin in two studies showed a decrease in central aortic PWV (caPWV), in one study, there was no change in caPWV and in other study, there was an increase in caPWV. In other five studies, fluvastatin reduced the brachial artery PWV. Antidiabetic drug, pioglitazone, reduced arterial stiffness in diabetic patients. 132 Rosiglitazone had variable effects on PWV, decreases 133 in one and no improvement in the other. 134 Metformin reduced arterial stiffness in young women with polycystic ovary syndrome.
135
Aminoguanidine decreased arterial stiffness in old rats, 136 streptozotocin-induced diabetic rats, 137 and in humans.
138
Alagebrium reduced arterial stiffness in older monkeys, 111 in older patients with isolated systolic HTN, 112 and in rat aging model.
139
Perspectives
Arterial stiffness and blood pressure pulsation are related. It is, however, not fully understood if there is a temporal relationship between arterial stiffness and elevation of blood pressure. Kaess et al 140 have shown that high aortic stiffness was associated with higher risk of incident HTN. These investigators also reported that initial blood pressure was not associated with progressive aortic stiffness. It has been, however, reported that aortic stiffness is greatly associated with age, HTN, obesity, impaired glucose tolerance, and dyslipidemia. 141, 142 As mentioned earlier 76,77 HTN and arterial stiffness functionally interact bidirectionally. It has been suggested that arterial stiffness should be taken into consideration in the management of HTN. 143 Arterial stiffness may be causal factor for HTN because PWV is elevated even when the arterial pressure is at borderline of HTN.
144
Traditional antihypertensive drugs such as ACE inhibitors, angiotensin II type 2 receptor antagonists, and β blockers reduce the arterial stiffness indirectly by lowering blood pressure but not through changes in the extracellular matrix. AGE-RAGE axis may be involved in the pathogenesis of essential HTN, and hence, the treatment target for essential HTN should include the agents that prevent the AGE-induced degradation of elastic fibers and formation of collagen fibers. Inhibition of AGE formation, blockade of AGE-RAGE interaction, and suppression of RAGE expression may be novel therapeutic strategies for treatment of arterial stiffness and HTN.
Conclusion
In conclusion, the data suggest that AGE-RAGE axis is involved in the development of arterial stiffness and HTN especially isolated systolic HTN. The studies also suggest that reduction of AGE formation and consumption, suppression of RAGE expression, elevation of sRAGE, and exogenous administration of recombinant sRAGE may be novel therapeutic strategies for the management of arterial stiffness/ HTN. It will be of benefit to add these new therapeutic agents in addition to traditional antihypertensive agents in the management of arterial stiffness, increased PP, and HTN.
